<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019821</url>
  </required_header>
  <id_info>
    <org_study_id>SuperBolus</org_study_id>
    <nct_id>NCT04019821</nct_id>
  </id_info>
  <brief_title>Super-Bolus: Effects on Postprandial Glycemia After High Glycemic Index Meal</brief_title>
  <official_title>Effects of Super-Bolus on Postprandial Glycemia After High Glycemic Index Meal in Children With Type 1 Diabetes Mellitus- Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Warsaw</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Warsaw</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to determine whether Super-Bolus is more effective in postprandial
      glycemic control than Normal-Bolus after the high glycemic index (H-GI) meal in children with
      type 1 diabetes (T1DM) treated with insulin pump (continuous subcutaneous insulin infusion,
      CSII).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postprandial Glycemia</measure>
    <time_frame>60 minutes after the prandial bolus</time_frame>
    <description>Postprandial blood glucose excursion measured by self monitoring of blood glucose (SMBG)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia Episodes</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
    <description>Hypoglycemia defined as a plasma glucose concentration below 70mg/dl with or without symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Area Under the Curve (AUC)</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
    <description>Measurements based on Continuous Glucose Monitoring System (CGMS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean amplitude of glycaemic excursion (MAGE)</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
    <description>MAGE will be defined as a standard deviation of blood glucose (SDBG) obtained from all blood glucose concentrations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Capillary blood glucose level 30,90,120,150,180 min after administration of the prandial bolus</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
    <description>measured by self monitoring of blood glucose (SMBG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic rise (GR)</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
    <description>a difference between baseline and the maximum glucose value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak glucose level (PG)</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
    <description>the maximum value of glycemia during 3 hours of postmeal time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to glucose peak</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time in postprandial glucose range between 70 to 180 mg/dl (4.0-10.0 mmol/L)</measure>
    <time_frame>3-hours after the prandial bolus</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Normal Bolus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pre-breakfast insulin will be given as a Normal Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Normal Bolus will be calculated based on individual insulin-to-carbohydrate ratio (ICR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Super Bolus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-breakfast insulin will be given as a Super Bolus 15 minutes before the high-glycemic index meal (cornflakes and milk). The Super Bolus will be calculated based on individual ICR increased to 150% and basal insulin will be suspended for 2 hours at the same time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glulisine</intervention_name>
    <description>A type of bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial.</description>
    <arm_group_label>Normal Bolus</arm_group_label>
    <arm_group_label>Super Bolus</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Aspart</intervention_name>
    <description>A type of bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial.</description>
    <arm_group_label>Normal Bolus</arm_group_label>
    <arm_group_label>Super Bolus</arm_group_label>
    <other_name>NovoRapid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>A type of bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial.</description>
    <arm_group_label>Normal Bolus</arm_group_label>
    <arm_group_label>Super Bolus</arm_group_label>
    <other_name>Humalog, Liprolog</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  duration of type 1 diabetes longer than 12months

          -  insulin pump therapy longer than 3 months

          -  written informed consent by patients and parents

        Exclusion Criteria:

          -  withdrawal of consent to participate in the study

          -  diabetes related complications (e.g. nephropathy)

          -  celiac disease

          -  any disease judged by the investigator to affect the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnieszka Szypowska, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Pediatrics, Medical University of Warsaw</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilia Kowalczyk</last_name>
    <phone>+48 223179538</phone>
    <email>kowalczykemilia91@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnieszka Szypowska, Prof.</last_name>
    <phone>+48 223179539</phone>
    <email>agnieszka.szypowska@gmail.com</email>
  </overall_contact_backup>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 11, 2019</study_first_submitted>
  <study_first_submitted_qc>July 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>May 27, 2020</last_update_submitted>
  <last_update_submitted_qc>May 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>super bolus</keyword>
  <keyword>diabetes type 1</keyword>
  <keyword>insulin bolus</keyword>
  <keyword>high glycemic index meal</keyword>
  <keyword>prandial insulin requirement</keyword>
  <keyword>postprandial glycemia</keyword>
  <keyword>insulin pump therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Aspart</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

